These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 18571222)

  • 1. Prothrombotic effect of Rofecoxib in a murine venous thrombosis model.
    Nagai N; Hoylaerts MF; Gallacher DJ; Lu HR; Lijnen HR
    Thromb Res; 2008; 122(5):668-73. PubMed ID: 18571222
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rofecoxib impairs adipose tissue development in a murine model of nutritionally induced obesity.
    Lijnen HR; Van Hoef B; Lu HR; Gallacher DJ
    Thromb Haemost; 2008 Aug; 100(2):338-42. PubMed ID: 18690356
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Obesity promotes injury induced femoral artery thrombosis in mice.
    Nagai N; Hoylaerts MF; Cleuren AC; Van Vlijmen BJ; Lijnen HR
    Thromb Res; 2008; 122(4):549-55. PubMed ID: 18234295
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Aspirin therapy: an attempt to explain the events of prothrombotic complications after treatment discontinuation.
    Doutremepuich C; Aguejouf O; Desplat V; Eizayaga FX
    Thromb Haemost; 2010 Jan; 103(1):171-80. PubMed ID: 20062937
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pioglitazone protects against thrombosis in a mouse model of obesity and insulin resistance.
    Bodary PF; Vargas FB; King SA; Jongeward KL; Wickenheiser KJ; Eitzman DT
    J Thromb Haemost; 2005 Oct; 3(10):2149-53. PubMed ID: 16194192
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Factor V Leiden mutation is associated with enhanced arterial thrombotic tendency in lean but not in obese mice.
    Nagai N; Lijnen HR; Cleuren AC; Rosendaal FR; Van Hoef B; Hoylaerts MF; Van Vlijmen BJ
    Thromb Haemost; 2007 Oct; 98(4):858-63. PubMed ID: 17938812
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Plasmin generation plays different roles in the formation and removal of arterial and venous thrombus in mice.
    Matsuno H; Kozawa O; Okada K; Ueshima S; Matsuo O; Uematsu T
    Thromb Haemost; 2002 Jan; 87(1):98-104. PubMed ID: 11848464
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Plasminogen activator inhibitor-1 contributes to the deleterious effect of obesity on the outcome of thrombotic ischemic stroke in mice.
    Nagai N; Van Hoef B; Lijnen HR
    J Thromb Haemost; 2007 Aug; 5(8):1726-31. PubMed ID: 17596132
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lipopolysaccharide augments venous and arterial thrombosis in the mouse.
    Wang X
    Thromb Res; 2008; 123(2):355-60. PubMed ID: 18448153
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Short-term ethinyl estradiol treatment suppresses inferior caval vein thrombosis in obese mice.
    Cleuren AC; van Hoef B; Hoylaerts MF; van Vlijmen BJ; Lijnen HR
    Thromb Haemost; 2009 Nov; 102(5):993-1000. PubMed ID: 19888539
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A murine model of deep vein thrombosis: characterization and validation in transgenic mice.
    Cooley BC; Szema L; Chen CY; Schwab JP; Schmeling G
    Thromb Haemost; 2005 Sep; 94(3):498-503. PubMed ID: 16268462
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of effects of rofecoxib on platelet function in an in vitro model of thrombosis with circulating human blood.
    Hernandez MR; Tonda R; Pino M; Serradell M; Arderiu G; Escolar G
    Eur J Clin Invest; 2004 Apr; 34(4):297-302. PubMed ID: 15086362
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Assessment of the number of cardio- and cerebrovascular events due to rofecoxib (Vioxx) in Germany between 2001 and 2004].
    Sawicki PT; Bender R; Selke GW; Klauber J; Gutschmidt S
    Med Klin (Munich); 2006 Mar; 101(3):191-7. PubMed ID: 16648975
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Increased venous versus arterial thrombosis in the Factor V Leiden mouse.
    Cooley BC; Chen CY; Schmeling G
    Thromb Res; 2007; 119(6):747-51. PubMed ID: 16793123
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The prothrombotic effects of leptin possible implications for the risk of cardiovascular disease in obesity.
    Konstantinides S; Schafer K; Loskutoff DJ
    Ann N Y Acad Sci; 2001 Dec; 947():134-41; discussion 141-2. PubMed ID: 11795261
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Role of fibrinolysis in obesity and thrombosis.
    Lijnen HR
    Thromb Res; 2009; 123 Suppl 4():S46-9. PubMed ID: 19303504
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Murine model of ferric chloride-induced vena cava thrombosis: evidence for effect of potato carboxypeptidase inhibitor.
    Wang X; Smith PL; Hsu MY; Ogletree ML; Schumacher WA
    J Thromb Haemost; 2006 Feb; 4(2):403-10. PubMed ID: 16420573
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rofecoxib, a selective cyclooxygenase-2 (COX-2) inhibitor increases pentylenetetrazol seizure threshold in mice: possible involvement of adenosinergic mechanism.
    Akula KK; Dhir A; Kulkarni SK
    Epilepsy Res; 2008 Jan; 78(1):60-70. PubMed ID: 18054463
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Increased thrombosis after arterial injury in human C-reactive protein-transgenic mice.
    Danenberg HD; Szalai AJ; Swaminathan RV; Peng L; Chen Z; Seifert P; Fay WP; Simon DI; Edelman ER
    Circulation; 2003 Aug; 108(5):512-5. PubMed ID: 12874178
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rofecoxib, a selective cyclooxygenase-2 (COX-2) inhibitor potentiates the anticonvulsant activity of tiagabine against pentylenetetrazol-induced convulsions in mice.
    Dhir A; Kulkarni SK
    Inflammopharmacology; 2006 Dec; 14(5-6):222-5. PubMed ID: 17139446
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.